BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 20389142)

  • 1. Prostatic duct adenocarcinoma: clinical characteristics, treatment options, and outcomes - a Rare Cancer Network study.
    Iğdem S; Spiegel DY; Efstathiou J; Miller RC; Poortmans PM; Koca S; Kiliç-Unsal D; Okkan S; Zietman A
    Onkologie; 2010; 33(4):169-73. PubMed ID: 20389142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
    Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
    J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcoma of the prostate: a single institutional review.
    Janet NL; May AW; Akins RS
    Am J Clin Oncol; 2009 Feb; 32(1):27-9. PubMed ID: 19194120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ductal prostate cancer: contemporary management and outcomes.
    Orihuela E; Green JM
    Urol Oncol; 2008; 26(4):368-71. PubMed ID: 18367098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
    Tavora F; Epstein JI
    Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.
    Jereczek-Fossa BA; Zerini D; Vavassori A; Fodor C; Santoro L; Minissale A; Cambria R; Cattani F; Garibaldi C; Serafini F; Matei VD; de Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):115-25. PubMed ID: 19004572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients.
    Ost P; Fonteyne V; Villeirs G; Lumen N; Oosterlinck W; De Meerleer G
    Eur Urol; 2009 Oct; 56(4):669-75. PubMed ID: 19501453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
    King CR; Presti JC; Gill H; Brooks J; Hancock SL
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.